SunTrust Banks Weighs in on Conatus Pharmaceuticals Inc.’s Q3 2017 Earnings (CNAT)

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) – Research analysts at SunTrust Banks lowered their Q3 2017 EPS estimates for Conatus Pharmaceuticals in a report released on Thursday. SunTrust Banks analyst J. Boris now expects that the biotechnology company will post earnings per share of ($0.06) for the quarter, down from their previous forecast of ($0.03). SunTrust Banks also issued estimates for Conatus Pharmaceuticals’ Q4 2017 earnings at ($0.14) EPS, FY2017 earnings at ($0.53) EPS and FY2021 earnings at $2.44 EPS.

Several other analysts have also issued reports on CNAT. Stifel Nicolaus restated a “buy” rating and issued a $10.00 price objective on shares of Conatus Pharmaceuticals in a research note on Thursday, August 3rd. Zacks Investment Research upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Aegis restated a “buy” rating and issued a $11.00 price objective on shares of Conatus Pharmaceuticals in a research note on Monday, May 15th. ValuEngine upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 24th. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Conatus Pharmaceuticals in a research note on Thursday, June 29th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $13.39.

COPYRIGHT VIOLATION WARNING: “SunTrust Banks Weighs in on Conatus Pharmaceuticals Inc.’s Q3 2017 Earnings (CNAT)” was originally posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/19/suntrust-banks-weighs-in-on-conatus-pharmaceuticals-inc-s-q3-2017-earnings-cnat-updated.html.

Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 5.52 on Monday. The firm has a 50-day moving average price of $5.83 and a 200-day moving average price of $5.59. The firm’s market cap is $155.13 million. Conatus Pharmaceuticals has a 12-month low of $1.45 and a 12-month high of $9.40.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.02. The business had revenue of $10 million during the quarter, compared to analysts’ expectations of $9.33 million. During the same quarter in the prior year, the business earned ($0.30) earnings per share.

Institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC increased its position in Conatus Pharmaceuticals by 641.1% in the second quarter. Acadian Asset Management LLC now owns 1,097,945 shares of the biotechnology company’s stock valued at $6,324,000 after buying an additional 949,785 shares during the last quarter. Renaissance Technologies LLC increased its position in Conatus Pharmaceuticals by 28.1% in the first quarter. Renaissance Technologies LLC now owns 235,290 shares of the biotechnology company’s stock valued at $1,358,000 after buying an additional 51,590 shares during the last quarter. Schwab Charles Investment Management Inc. purchased a new position in Conatus Pharmaceuticals during the second quarter valued at approximately $1,041,000. Bank of New York Mellon Corp increased its position in Conatus Pharmaceuticals by 62.3% in the second quarter. Bank of New York Mellon Corp now owns 130,343 shares of the biotechnology company’s stock valued at $751,000 after buying an additional 50,033 shares during the last quarter. Finally, Courage Capital Management LLC increased its position in Conatus Pharmaceuticals by 25.0% in the first quarter. Courage Capital Management LLC now owns 125,000 shares of the biotechnology company’s stock valued at $721,000 after buying an additional 25,000 shares during the last quarter. 22.53% of the stock is currently owned by institutional investors.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply